Despite the need for effective vancomycin therapy, there are few data guiding vancomycin monitoring in children. We reviewed retrospectively vancomycin use in children 1 month to 12 years of age. Initial and adjusted target trough vancomycin concentrations in serum were infrequently achieved regardless of the dosing schedule. Currently recommended trough concentrations need to be re-examined with a more detailed pharmacokinetic study in children.
Introduction
The population of northern Australia experiences a heavy burden of staphylococcal disease, heterogeneous VISA proliferate at vancomycin trough serum concentrations of less than 10 mg/L, 4 together with evidence from one prospective study suggesting clinical efficacy was optimum when the vancomycin AUC 24 /MIC ratio was at least 345 mg*m/L. 5 Furthermore, decreasing efficacy has been observed with higher vancomycin MICs which are still in the susceptible range. 6, 7 Although increasing trough concentrations may be desirable for reasons of efficacy and resistance selection, the change is not currently supported by clinical trial data in adults or children.
3 Surprisingly, even before the recent emphasis on achieving higher trough vancomycin concentrations, there were only a very small number of pharmacokinetic studies and no Vancomycin has traditionally been administered in 6-hourly doses in children. However, in
March 2010, RDH developed a new vancomycin protocol in accordance with the revised ATG. were compared using Fisher's exact test, continuous measures using Student's t-test or analysis of variance, and rank-sum test for normally-distributed and non-parametric data respectively, using STATA, version 11.0 (StataCorp, Texas, USA). A p value of < 0.05 was considered significant.
Results
The demographics of 37 children 1-12 years of age who had at least one valid trough serum vancomycin concentration measured are shown in Table 1 . Seventeen patients were commenced on a 6-hourly vancomycin dosing, 20 were given 12-hourly vancomycin dosing, while two
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patients initially received a loading dose before one started a 6-hourly dosing regime and the other commenced a12-hourly dosing regime. Patients given 6-hourly vancomycin dosing had a lower initial total vancomycin daily dose (mg/kg) compared with patients receiving 12-hourly vancomycin dosing (p=0.002), reflecting the changeover period between vancomycin dosing protocols (see Table, SDC 1). Ten children initially received daily vancomycin doses of less than 45mg/kg/d in 6-hourly doses, half of which occurred before the change in protocol to 30mg/kg 12-hourly. Of the ten children, nine were less than 6 years of age. The median duration of vancomycin therapy was 6 days for both 6-hourly (IQR 3-10 days) and 12-hourly (IQR 2-13 days) dosing groups, suggesting that clinical efficacy was similar in both groups (p=0.94).
Thirteen patients 1-12 years of age had an initial vancomycin trough concentration of <5 mg/L (see Table, One hundred and twenty repeat adjusted vancomycin trough concentrations were obtained on 26 children 1-12 years of age (see Table, Within all dosing groups patients less than 6 years of age had significantly lower repeat trough concentrations than older patients (p=<0.001), despite receiving similar daily doses of vancomycin (p=0.51; Table 1 ).
Eleven patients 1-11 months of age (median age 5.9 months, IQR 4.2-7.6) were commenced on vancomycin; eight on 6-hourly dosing (median daily dose 56 mg/kg, IQR 40. however, this has been difficult to achieve in children and doses of up to 85 mg/kg per day have been recommended for serious MRSA infections, based on pharmacokinetic modeling rather than on clinical data. 10 The ATG recommends 30mg/kg 12-hourly in children with target trough concentrations of 12-18mg/L, based on the premise that a 12-hourly dosing interval is more convenient for administration than a 6-hourly interval and will have a similar AUC as a 6-hourly dosing interval using the same total daily dose.
A common error in vancomycin monitoring is using trough concentration target ranges without accounting for the dosing frequency. For a particular total daily dose of vancomycin, the same AUC, and presumably the same efficacy, will be achieved whether the total daily dose is given in 6-hourly or 12-hourly dosing intervals. However, trough concentrations will be different for the same total daily dose when different dosing frequencies are used -despite the same total vancomycin exposure and AUC. For example, steady state trough concentrations with 6-hourly dosing will be twice as high as those of 12-hourly dosing with the same daily dose, despite the Copyright © 2012 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
same AUC. 11 Prescribers need to be aware that different target troughs should be selected for different dosing frequencies.
But are trough concentrations the correct therapeutic target for monitoring vancomycin therapy in children? There is concern that vancomycin dose adjustment in children may be overly aggressive to meet the new target trough concentrations, which have been driven by studies in adults using adult pharmacokinetics. AUC 24 /MIC is the primary predictive pharmacodynamic index for vancomycin efficacy in treating S. aureus and the use of trough vancomycin concentrations to monitor efficacy is based on the assumption made for adults receiving 12-hourly dosing that serum trough vancomycin concentrations are reasonably correlated with AUC 24 . In our study, children who were younger than 6 years old had lower repeat adjusted serum vancomycin trough concentrations compared with children older than 6 years of age, independent of total daily dose and dosing frequency, suggesting that the clearance of vancomycin is higher in young children. Because clearance is higher in young children, young children would likely need different trough targets than adults to achieve the target AUC 24 . In addition, since it is not known what these trough targets should be in the pediatric population, it makes more sense to monitor AUC 24 directly. The AUC 24 /MIC ratio for efficacy targeting 400
mg.hr/L may be a more accurate and safe method of therapeutic drug monitoring in children.
Based on our preliminary results, currently recommended trough concentrations need to be reexamined with a more detailed pharmacokinetic study in children which examines the effects of different doses, different schedules, AUC 24 and trough concentrations. Further, target trough concentrations, if they continue to be used, should be adjusted for dosing schedule. Based on our preliminary data, for children at our hospital in whom vancomycin is continued as the definitive treatment we are developing a guideline where the AUC24 is used to direct therapy, aiming for a 
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